GlassScriptPhysician profile
Christopher Reid Thomas
NPI 1831202480
$2,651.65
in general payments reported to CMS, 2019-2025
31 companies · $260 in 2025
The $260 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $216 · 2021: $123 · 2022: $190 · 2023: $847 · 2024: $1,016 · 2025: $260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,123.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,122.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $324.98 | 2023-2025 | Opdivo, Abecma, Opdualag |
| Daiichi Sankyo INC. | $227.73 | 2023-2025 | Enhertu |
| Galvanize Therapeutics, INC | $222.32 | 2023 | Aliya System |
| Kite Pharma, INC. | $215.40 | 2019-2023 | Yescarta |
| Boston Scientific Corporation | $144.17 | 2022 | |
| Amgen INC. | $138.71 | 2019-2024 | |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Incyte Corporation | $122.71 | 2021 | |
| Genmab U.S., INC. | $121.87 | 2025 | Epkinly |
| Springworks Therapeutics, INC. | $121.80 | 2024 | Ogsiveo |
| Abbvie INC. | $120.16 | 2023-2025 | Venclexta |
| Rigel Pharmaceuticals, INC. | $115.98 | 2024 | Tavalisse, Rezlidhia |
| Pharmacyclics LLC, An Abbvie Company | $109.79 | 2019 | |
| Aveo Pharmaceuticals, INC. | $96.38 | 2024 | |
| Blueprint Medicines Corporation | $69.75 | 2023 | Ayvakit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $45.88 | 2024 | Plasmablade(Tm) |
| Novartis Pharmaceuticals Corporation | $45.85 | 2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $42.83 | 2023 | |
| Taiho Oncology, INC. | $28.65 | 2025 | |
| Astellas Pharma US INC | $28.08 | 2025 | Padcev |
| Janssen Biotech, INC. | $23.12 | 2023 | Imbruvica, Tecvayli, Erleada |
| Pfizer INC. | $22.92 | 2024 | |
| Recordati_rare_diseases_inc. | $22.76 | 2023 | Panhematin |
| Atricure, INC. | $22.25 | 2022 | |
| Merck Sharp & Dohme LLC | $21.68 | 2024 | Lynparza, Keytruda |
| Lilly USA, LLC | $21.04 | 2024 | Verzenio, Jaypirca, Retevmo |
| Emd Serono, INC. | $18.26 | 2024 | |
| Genentech USA, INC. | $18.06 | 2025 | Polivy |
| Astrazeneca Pharmaceuticals LP | $13.52 | 2023 | Tagrisso |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.